Impact of the KEYNOTE-045 Study Comparing Pembrolizumab and Chemotherapy in Bladder Cancer
Joaquim Bellmunt, MD, PhD, attending physician of Solid Tumor Oncology at Dana-Farber Cancer Institute, discusses the impact of the phase III KEYNOTE-045 study, which compared second- or third-line pembrolizumab with investigator-choice chemotherapy as a treatment for patients with metastatic or locally advanced, unresectable urothelial carcinoma. All patients in the study had recurred or progressed following platinum-based chemotherapy.
MRD Negativity Improves With D-VRd in Newly Diagnosed, Transplant-Eligible Myeloma
September 6th 2024Updated findings from the PERSEUS study found that patients with newly diagnosed multiple myeloma benefited from a treatment regimen involving daratumumab, bortezomib, lenalidomide, and dexamethasone before and after autologous stem cell transplant.
Read More
